TNGXMEDIUM SIGNALFINANCIAL10-K

TNGX significantly strengthened its financial position with a 32% increase in outstanding shares, 73.5% jump in stockholders' equity to $346.2M, and substantial debt reduction of 55.1%.

The company appears to have completed a significant equity raise that funded operations and paid down liabilities, providing a stronger balance sheet foundation. However, the 32% dilution in share count (from 108M to 143M shares) represents meaningful dilution for existing shareholders that investors should carefully evaluate against the improved financial stability.

Comparing 2026-03-05 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

TNGX demonstrated strong overall financial improvement with revenue growing 48.3% to $62.4M and operating losses narrowing by 23.6% to -$111.3M, indicating improving operational efficiency. The balance sheet was substantially strengthened through what appears to be an equity raise, with cash increasing 61.5% to $112.3M, total liabilities declining 55.1%, and stockholders' equity surging 73.5% to $346.2M. While the 32% share dilution is notable, the overall picture suggests TNGX has secured adequate funding to support operations while reducing financial risk through debt paydown.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+73.5%
$199.5M→$346.2M

Equity base grew 73.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+61.5%
$69.5M→$112.3M

Cash position surged 61.5% — strong cash generation or capital raise providing significant financial cushion.

Total Liabilities
Balance Sheet
-55.1%
$117.0M→$52.5M

Liabilities reduced 55.1% — deleveraging improves balance sheet strength and financial flexibility.

Revenue
P&L
+48.3%
$42.1M→$62.4M

Strong top-line growth of 48.3% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
-43.2%
$38.2M→$21.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
+39%
$754K→$1.0M

Capital expenditure jumped 39% — major investment cycle underway; assess returns on deployment.

Current Assets
Balance Sheet
+32.8%
$266.3M→$353.8M

Current assets grew 32.8% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+26%
$316.5M→$398.7M

Asset base grew 26% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
+23.6%
-$145.6M→-$111.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+22%
-$130.3M→-$101.6M

Net income grew 22% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-02-27
ADDED
As of February 26, 2026, the registrant had 142,688,851 shares of common stock, $0.001 par value per share, outstanding.
Inadequate funding for government agencies in or outside the United States, including from government shutdowns or other disruptions to these agencies' staffing and operations, could prevent new products and services being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.
has the potential to support a chemotherapy-free first line pancreatic cancer pivotal study and potentially second-line therapies in MTAP-deleted/RAS mutated patients; and other risks and uncertainties, including those listed in Part I, Item 1A of this Annual Report on Form 10-K under the section titled Risk Factors.
2025 Annual Report means this Annual Report on Form 10-K for the year ended December 31, 2025; ii.
We leverage our state-of-the-art target and drug discovery platforms to identify novel disease-relevant targets and develop medicines tailored to defined patient populations with high unmet medical need.
We are currently focused on clinical development of two MTAP-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, our next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM).
In October 2025, we reported positive data from the ongoing Phase 1/2 clinical trial of vopimetostat monotherapy in patients with MTAP-deleted selective cancers, illustrating clinical activity across multiple cancer types with a favorable safety and tolerability profile.
Specifically, the data in second-line MTAP-deleted pancreatic cancer demonstrated a median progression free survival (mPFS) of 7.2 months and 25% objective response rate (ORR), supporting the planned initiation of a 2L pivotal trial in this patient population in 2026.
The histology selective cohort, which excludes sarcoma, pancreatic and lung cancer patients, also showed positive data, with a mPFS of 9.1 months and 49% ORR.
REMOVED
As of February 19, 2025, the registrant had 108,107,890 shares of common stock, $0.001 par value per share, outstanding.
2024 Annual Report means this Annual Report on Form 10-K for the year ended December 31, 2024; ii.
We leverage our state-of-the-art target discovery platform to identify novel targets and develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need.
Tumor suppressor gene loss remains a largely unaddressed target space specifically because these genetic events cannot be directly targeted.
We also are extending this target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss to include the discovery of novel targets that reverse tumor suppressor gene mediated immune evasion which prevents the immune system from recognizing and killing cancer cells.
We are currently developing two MTA-cooperative PRMT5 inhibitors: TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, our next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM.
In November 2024, we reported positive early data from the ongoing Phase 1/2 clinical trial of TNG462, demonstrating durable clinical activity across multiple cancer types with a good safety and tolerability profile.
We are currently enrolling patients in the ongoing TNG462 Phase 1/2 monotherapy clinical trial and plan to provide a clinical data update on TNG462 in 2025.
Additionally, we plan to begin enrollment in multiple combinations involving TNG462 in 2025.
We have initiated a robust clinical development program for TNG462, and plan to pursue monotherapy registrational clinical trials in 2026.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →